samedan logo
 
 
 
spacer
home > ebr > summer 2004 > the ipo window reopens - are you ready?
PUBLICATIONS
European Biopharmaceutical Review

The IPO Window Reopens - Are you Ready?

Whisper it quietly, but the IPO window may just have reopened for European biotechs. Ark Therapeutics' flotation in March this year has led to a spate of similar launches of biotech stocks onto the public markets after a dearth of opportunities in recent years. The position undoubtedly remains volatile. Only the best companies will be allowed to list and, as ever, due diligence will be key. This article looks at the importance of legal due diligence in the context of an impending IPO and asks are you ready to take advantage of the IPO window - which may yet prove shortlived.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Patrick Martin, Partner and Martin Finnegan, Senior Solicitor at McGrigors

Patrick Martin is a Partner and Corporate and Commercial Lawyer at McGrigors, with a particular emphasis on the health care and life sciences fields, acting for both investors and companies. He has advised on numerous technology start-ups and spin-outs, fundraisings and private placements for biotech companies and IPOs. Patrick has specialised in private equity work for over 14 years.


Martin Finnegan is a senior Corporate Solicitor at McGrigors and part of the firm's public equity group. Martin has advised on numerous IPOs and public equity issues acting for sponsors and companies, and is a member of the legal committee of the Quoted Companies Alliance (QCA).

spacer
Patrick Martin
spacer
spacer
spacer
Martin Finnegan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Restructure Announcement at Illingworth

As a rapidly growing company, Illingworth Research Group (Illingworth) has reflected on its goals, accomplishments and ambitious future growth plans. This has allowed us to consider opportunities for staff to explore their own growth and development possibilities within a rapidly changing landscape. With that in mind, Illingworth are announcing some significant and exciting changes to our organization. Illingworth remain committed to making patient involvement in clinical trials as stress free as possible and our strengthened management team and launch of our patient concierge service, PatientGO, in combination with global, mobile research nursing will ensure as many patients as possible have the chance to participate in the development of critical drugs, regardless of their geography or socioeconomic class.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement